[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643410":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":31,"locations":22,"responsibleParty":37,"collaborators":22,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":22,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":22,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":22,"overallStatus":66,"whyStopped":22,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":22},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-FAPI-PSMA PET\u002FCT Imaging","EXPERIMENTAL","Participants with suspected or confirmed solid tumors will undergo PET\u002FCT imaging using the investigational tracer 68Ga-FAPI-PSMA. Imaging findings will be compared with PET\u002FCT performed using standard tracers such as 68Ga-PSMA-617 or 68Ga-FAPI-04 to evaluate the diagnostic performance of the dual-targeted tracer.",[13,14,15],"Radiation: 68Ga-FAPI-PSMA","Radiation: 68Ga-PSMA-617","Radiation: 68Ga-FAPI-04",[17,23,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"RADIATION","68Ga-FAPI-PSMA","Participants will receive an intravenous injection of the investigational PET tracer 68Ga-FAPI-PSMA (0.1-0.15 mCi\u002Fkg). Whole-body PET\u002FCT imaging will be performed approximately 1 hour after injection. Delayed imaging at 2-4 hours may be performed when necessary. Imaging results will be used to evaluate tracer uptake in tumor lesions and to assess the diagnostic performance of the dual-targeted tracer.",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"68Ga-PSMA-617","Participants will receive an intravenous injection of the PET tracer 68Ga-PSMA-617 (0.1-0.15 mCi\u002Fkg) followed by PET\u002FCT imaging approximately 1 hour after administration. This imaging serves as a comparator to evaluate the diagnostic performance of the investigational tracer 68Ga-FAPI-PSMA.",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"68Ga-FAPI-04","Participants may undergo PET\u002FCT imaging using the PET tracer 68Ga-FAPI-04 (0.1-0.15 mCi\u002Fkg) with imaging performed approximately 1 hour after injection. This imaging will serve as a comparator for assessing the diagnostic performance of 68Ga-FAPI-PSMA PET\u002FCT.",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":22,"email":36},"yifei pei","CONTACT","+86 15602222734","peiyfiei0523@163.com",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Hua Zhu","Professor","100643410","68ga-fapi-psma-pet-imaging-for-the-diagnosis-of-solid-tumors-100643410",false,"NCT07639801","68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors","Evaluation of Dual-Targeted 68Ga-FAPI-PSMA PET\u002FCT for the Diagnosis and Staging of Solid Tumors","Inclusion Criteria:\n\n* Age 18-75 years\n\n  * Patients with suspected or confirmed solid tumors (e.g., prostate cancer, hepatocellular carcinoma, ovarian cancer, or endometrial cancer)\n  * Patients scheduled to undergo tumor biopsy or surgical treatment within 2 months\n  * ECOG performance status of 0 or 1\n  * Expected survival of at least 12 weeks\n  * Adequate hematologic and organ function:\n  * White blood cell count ≥ 4.0 × 10\\^9\u002FL or neutrophils ≥ 1.5 × 10\\^9\u002FL\n  * Platelet count ≥ 100 × 10\\^9\u002FL\n  * Hemoglobin ≥ 90 g\u002FL\n  * Total bilirubin ≤ 1.5 × upper limit of normal (ULN)\n  * ALT\u002FAST ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases)\n  * Creatinine ≤ 1.5 × ULN\n  * At least one measurable lesion according to RECIST 1.1 criteria\n  * Ability to understand the study procedures and willingness to sign written informed consent\n\nExclusion Criteria:\n\n* Severe hepatic or renal dysfunction\n* Inability to remain in a supine position for approximately 30 minutes during PET\u002FCT scanning\n* Refusal or inability to participate in the clinical study\n* Claustrophobia or severe psychiatric disorders that would interfere with imaging procedures\n* Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study","ALL","18 Years","75 Years",{"count":52,"type":53},20,"ESTIMATED","INTERVENTIONAL",[56],"NA","This study aims to evaluate a novel dual-targeted PET imaging tracer, 68Ga-FAPI-PSMA, for the detection and evaluation of solid tumors. Fibroblast activation protein (FAP) and prostate-specific membrane antigen (PSMA) are two important molecular targets that are highly expressed in tumor cells or the tumor microenvironment. Combining these two targets into a single imaging probe may improve the sensitivity and accuracy of tumor detection.\n\nIn this single-center, open-label, self-controlled study, approximately 20 patients with suspected or confirmed solid tumors will undergo PET\u002FCT imaging using 68Ga-FAPI-PSMA. The imaging results will be compared with standard PET tracers such as 68Ga-PSMA-617 or 68Ga-FAPI-04. The study will assess tracer uptake in tumor lesions and compare diagnostic performance between imaging methods. The results may help determine whether 68Ga-FAPI-PSMA PET\u002FCT can improve tumor detection, staging, and clinical evaluation in patients with solid tumors.",[59,60,61,62,63,64,65],"Prostate Cancer","Hepatocellular Carcinoma","Ovarian Cancer","Solid Tumors","Endometrial Cancer","FAPI","PSMA","NOT_YET_RECRUITING","2026-06-06",{"date":69,"type":70},"2026-06-10","ACTUAL",{"date":72,"type":53},"2026-06",{"date":74,"type":53},"2026-12-31",{"name":5,"class":6}]